Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1970-1978

  Patra, Chitta Ranjan ^a   Bhattacharya, Resham ^a   Wang, Enfeng ^a   Katarya, Aaron ^a   Lau, Julie S ^a   Dutta, Shamit ^a   Muders, Michael ^a   Wang, Shanfeng ^b,c   Buhrow, Sarah A ^b   Safgren, Stephanie L ^b   Yaszemski, Michael J ^b   Reid, Joel M ^b   Ames, Matthew M ^b   Mukherjee, Priyabrata ^a,b   Mukhopadhyay, Debabrata ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c University of Tennessee Knoxville   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GOLD; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; IMMUNOCONJUGATES; METAL NANOPARTICLES; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 40949151239     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6102     Document Type: Article

References (41)

1. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with respectable pancreatic adenocarcinoma. Ann Surg Oncol 2004;11:644-9.
2. Shore S, Vimalachandran D, Raraty MG, Ghaneh P. Cancer in the elderly: pancreatic cancer. Surg Oncol 2004;13:201-210.
3. Langer R. Drug delivery and targeting. Nature 1998;392:5-10.
4. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
5. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29:31-7.
6. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
7. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
8. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1:719-32.
9. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13.
10. Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34:427-32.
11. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33 Suppl 1:S18-22.
12. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-4.
13. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312:1027-30.
14. Zharov VP, Kim JW, Curiel DT, Everts M. Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine 2005;1:326-45.
15. Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res 2003;63:1999-2004.
16. Mukherjee P, Bhattacharya R, Bone N, et al. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology 2007;5:4.
17. Mukherjee P, Bhattacharya R, Wang P, et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005;11:3530-4.
18. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett 2005;5:829-34.
19. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 2006;239:129-35.
20. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol 2004;22:47-52.
21. Xu X, Han MS, Mirkin CA. A gold-nanoparticle-based real-time colorimetric screening method for endonuclease activity and inhibition. Angew Chem Int Ed Engl 2007;46:3468-70.
22. You CC, Miranda OR, Gider B, et al. Detection and identification of proteins using nanoparticle-fluorescent polymer "chemical nose" sensors. Nat Nanotech 2007;2:318-23.
23. Whitesides GM. The "right" size in nanobiotechnology. Nat Biotechnol 2003;21:1161-5.
24. Whitesides GM, Kriebel JK, Love JC. Molecular engineering of surfaces using self-assembled monolayers. Sci Prog 2005;88:17-48.
25. Higby GJ. Gold in medicine: a review of its use in the West before 1900. Gold Bull 1982;15:130-40.
26. Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004;104:293-46.
27. Boal AK, Ilhan F, DeRouchey JE, Thurn-Albrecht T, Russell TP, Rotello VM. Self-assembly of nanoparticles into structured spherical and network aggregates. Nature 2000;404:746-8.
28. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol 2006;79:248-53.
29. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004;15:897-900.
30. Zahr AS, de Villiers M, Pishko MV. Encapsulation of drug nanoparticles in self-assembled macromolecular nanoshells. Langmuir 2000;21:403-10.
31. Bhattacharya R, Patra CR, Verma R, Kumar S, Greipp PR, Mukherjee P. Gold nanoparticles inhibit proliferation of multiple myeloma cells. Adv Mater 2007;19:711-6.
32. Bhattacharya R, Mukherjee P, Xiong Z, Atala A, Soker S, Mukhopadhyay D. Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells. Nano Lett 2004;4:2479-81.
33. Bhattacharya R, Patra CR, Earl A, et al. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomed 2007;3:224-38.
34. Stephan S, Datta K, Wang E, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004;10:6993-7000.
35. Freeman KB, Anliker S, Hamilton M, et al. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1995;665:171-81.
36. Mangeney C, Ferrage F, Aujard I, et al. Synthesis and properties of water-soluble gold colloids covalently derivatized with neutral polymer monolayers. J Am Chem Soc 2002;124:5811-21.
37. Bhattacharya R, Patra CR, Wang S, et al. Assembly of gold nanoparticles in a rod-like fashion using proteins as templates. Adv Funct Mater 2006;16:395-400.
38. Bourg MC, Badia A, Lennox RB. Gold-sulfur bonding in 2D and 3D self-assembled monolayers: XPS characterization. J Phys Chem B 2000;104:6562-7.
39. Kumar A, Mukherjee P, Guha A, et al. Amphoterization of colloidal gold particles by capping with valine molecules and their phase transfer from water to toluene by electrostatic coordination with fatty amine molecules. Langmuir 2000;16:9775-83.
40. Demers LM, Ostblom M, Zhang H, Jang NH, Liedberg B, Mirkin CA. Thermal desorption behavior and binding properties of DNA bases and nucleosides on gold. J Am Chem Soc 2002;124:11248-9.
41. Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 2002;102:101-8.